• Explore /
  • Poster
  • / Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.

Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.

Abstract Poster

Authors

Andrew Ko

Andrew H. Ko

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Andrew H. Ko , Margaret A. Tempero , Tanios B. Bekaii-Saab , Peter Kuhn , Ryan Courtin , Sharvina Ziyeh , Sanaa Tahiri , Robin Katie Kelley , Elizabeth Dito , Anna Ong , Regina Linetskaya , Olga K. Mirzoeva , Christina Sing-Ying Wu , Alan Paul Venook , Wolfgang Michael Korn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01222689

Citation

J Clin Oncol 31, 2013 (suppl; abstr 4014)

DOI

10.1200/jco.2013.31.15_suppl.4014

Abstract #

4014

Poster Bd #

6

Abstract Disclosures

Similar Posters

First Author: Qing Zhou

First Author: Vincent M. Chung

First Author: Dirk Strumberg

First Author: Jesús Fuentes Antrás